Marker Therapeutics, Inc. cotiza a 1.01 USD y tiene una capitalización bursátil de $17M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selectiv…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.16 | $-0.04 | $-0.12 | $-0.29 |
| Estimado | $-0.19 | $-0.19 | $-0.21 | $-0.27 |
| Sorpresa | +15.8% | +78.9% | +42.9% | -7.4% |
| Métrica | MRKR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -363.4% | -38.6% | -324.8% |
| Net Margin | -343.0% | -33.6% | -309.4% |
| FCF Margin | — | -13.9% | — |
| ROE | -72.4% | -40.4% | -32.0% |
| ROA | -63.8% | -32.0% | -31.8% |
| Current Ratio | 8.39 | 2.84 | +5.55 |
| Debt / Equity | — | 0.28 | — |